NovaBridge Unveils Encouraging Phase 1 Dose Expansion Results at ESMO-IO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Yahoo Finance
Ragistomig Overview: Ragistomig is a bispecific antibody targeting 4-1BB and PD-L1, aimed at treating advanced solid tumors, particularly in patients resistant to checkpoint inhibitors.
Phase 1 Study Results: The Phase 1 study demonstrated that the new Q6W dosing schedule maintained anti-tumor efficacy while showing improved safety, with only 5% of patients experiencing significant liver function test elevations.
Immunological Findings: Positive immunological data indicated increased CD8+ T cell proliferation and memory T-cell activation, suggesting durable immune engagement and a favorable balance between effector and regulatory T cells.
Future Directions: The encouraging results support further combination studies of ragistomig, with ongoing evaluations of higher dosing cohorts to enhance treatment outcomes for patients with relapsed or refractory solid tumors.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like NBP with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on NBP
Wall Street analysts forecast NBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBP is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.870
Low
7.00
Averages
8.00
High
9.00
Current: 3.870
Low
7.00
Averages
8.00
High
9.00
No data
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NovaBridge Biosciences' Chairman Plans to Buy $5 Million in ADSs
- Chairman's Purchase Plan: Fu Wei, Executive Chairman of NovaBridge Biosciences, intends to purchase up to $5 million in the company's ADSs through his controlled entity in open market transactions, reflecting confidence in the company's future growth.
- Positive Clinical Data: The recent positive dose expansion data for givastomig from the Phase 1b study reinforces NovaBridge's clinical development capabilities and market potential in treating gastric cancer.
- Global Platform Development: NovaBridge is committed to accelerating access to innovative medicines by combining deep business development expertise with agile clinical development, showcasing the strategic value of its global biotechnology platform.
- Diverse Pipeline: The company's pipeline includes potential best-in-class therapies like givastomig and VIS-101, targeting gastric cancer and other malignancies, demonstrating its diversity and innovation in the biopharmaceutical sector.
Continue Reading
GT Biopharma Submits IND for GTB-5550 Targeting $362 Billion Solid Tumor Market
- Market Transformation: The precision medicine sector is projected to grow from $138 billion in 2026 to over $537 billion by 2035, marking a shift towards modular biologics that creates substantial market opportunities for companies like GT Biopharma.
- New Drug Application: GT Biopharma submitted an IND for GTB-5550 to the FDA in December 2025, targeting the B7-H3 protein to treat various solid tumors, which is expected to significantly enhance the company's competitiveness in cancer treatment.
- Clinical Trial Progress: The planned Phase 1 trial for GTB-5550 will evaluate its efficacy across seven distinct metastatic disease cohorts, potentially providing critical clinical data to further advance the company's product pipeline.
- Dual Program Advancement: GT Biopharma is concurrently advancing its Phase 1 trial of GTB-3650, having successfully treated multiple patients with a favorable safety profile, which is expected to significantly expand its addressable patient population.
Continue Reading